Following Cathie Wood: On the first trading day of the US stock market in 2026, added positions in AI healthcare company Tempus AI, and continued to adjust holdings in ROKU and RKLB.

On January 2, 2026, the US stock market welcomed the first trading day of the new year. The three major indices showed a divergence after the opening. $Dow Jones Industrial Average (.DJI.US)$ maintained a moderate upward trend, $Nasdaq Composite Index (.IXIC.US)$ while some heavyweight tech stocks dragged down the index slightly at the close, $S&P 500 Index (.SPX.US)$ and oscillated around the 6,860-point level.

Market funds did not become blindly optimistic with the arrival of the new year. There was a noticeable outflow from tech giants that had surged last year, shifting to seek defensive sectors or mid-cap growth stocks with better valuations. Although the semiconductor sector continued to show some strength, the overall market sentiment exhibited a 'cautious probing' characteristic.

On the first trading day of the US stock market in the new year, Cathie Wood, head of ARK Invest, executed a new portfolio adjustment. Her fund concentrated on buying several biotech stocks in their growth phase on this day, tactically reducing holdings in some heavily weighted and recently volatile tech stocks. This operation continued her long-term commitment to the field of 'disruptive innovation,' with capital flows continuing to tilt toward AI healthcare and biopharmaceutical sectors on the first day of the new year.

Focus of increased positions: Precision medicine and gene editing become key areas

Reviewing ARK Invest's buy list on January 2, the deep integration of AI technology and life sciences is the core logic behind the increased positions.

1. $Tempus AI (TEM.US)$ : Increased position by 88,800 sharesTempus AI (TEM), an AI precision healthcare data company, saw substantial增持, demonstrating confidence in the data-driven healthcare paradigm. Tempus AI is a leader in applying artificial intelligence to clinical data analysis, providing precise treatment solutions using big medical data processed through AI.

2. $Personalis (PSNL.US)$: Increased position by 880,000 sharesGenomic sequencing and cancer detection company Personalis Inc (PSNL) was bought with an additional 880,000 shares; the company’s technological accumulation in the field of tumor immunotherapy may be the core reason for ARK Fund's continued optimism.

3. $Beam Therapeutics (BEAM.US)$ : Increased position by 587,000 sharesBeam Therapeutics (BEAM), a pioneer in base editing technology, received an additional purchase of 587,000 shares, continuing ARK Invest's consistent support for next-generation gene-editing therapies.

4. $Kodiak AI (KDK.US)$ : Increased position by 227,000 sharesOphthalmic biopharmaceutical company Kodiak Sciences (KDK) saw its position increased by 227,000 shares due to its promising pipeline in retinal disease treatments.

5. $Twist Bioscience (TWST.US)$ : Increased position by 177,000 sharesSynthetic biology DNA manufacturing company Twist Bioscience (TWST) received an additional 177,000 shares, given its critical upstream position in the biotech supply chain and long-term growth logic.

The companies that saw their positions increased generally feature high R&D investment and high technological barriers, representing ARK Invest’s long-term confidence in the future transformation of healthcare paradigms.

Logic behind reducing positions: Weight control and tactical profit-taking

ARK Invest's reduction in positions on the day mainly focused on streaming media, e-commerce, and some mature life sciences stocks.

1. $Roku Inc (ROKU.US)$ : Reduced by 45,900 sharesRoku Inc (ROKU), a streaming hardware and platform company, has been reduced in holdings. As a long-term overweight position for ARK, this reduction appears to be more of a risk management measure to control the weight of a single holding.

2. $Rocket Lab (RKLB.US)$ : Reduced by 21,900 sharesRocket Lab USA (RKLB), a commercial space launch services company, sold 21,900 shares. This operation is a tactical profit-taking after the stock price experienced an earlier rise.

3. $Shopify (SHOP.US)$: Reduced by 20,600 sharesShopify Inc (SHOP), a global e-commerce SaaS platform, saw a reduction of 20,600 shares. The fund chose to release some liquidity during the rebound in the e-commerce sector to allocate towards other high-growth opportunities.

4. $Natera (NTRA.US)$ : Reduced by 7,436 sharesNatera Inc (NTRA), a genetic testing and diagnostics company, was slightly sold down by 7,436 shares. This move represents a standard dynamic adjustment of holdings without changing the long-term holding rationale.

5. $Ionis Pharmaceuticals (IONS.US)$ : Reduced by 4,819 sharesIonis Pharmaceuticals (IONS), an RNA-targeted drug development company, had 4,819 shares sold, representing a technical reduction at a high position for this mature biopharmaceutical target.

Futubull's [Opportunities Page] has launched a celebrity holdings opportunity portfolio tracker! Multiple celebrity portfolios to choose from,One-click tracking of top investors' layouts,Precisely lock in high-quality targets, making investments with more confidence!

258K Views